{
  "id": 3051869,
  "title": "FDA delays Capricor's deramiocel PDUFA date to review new data",
  "url": "https://urgent.news/2026/08/24/fda-delays-capricors-deramiocel-pdufa-date-to-review-new-data",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-24T15:10:23.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/fda-delays-capricors-deramiocel-pdufa-date-to-review-new-data/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The FDA is pushing back its decision on Capricor Therapeutics’ problematic Duchenne muscular dystrophy therapy to review additional data for a more niche indication. The company on Monday said the agency has extended the PDUFA ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "BioPharma Dive",
        "title": "FDA extends review of Capricor cell therapy; Pain drug startup to go public",
        "url": "https://urgent.news/2026/08/24/fda-extends-review-of-capricor-cell-therapy-pain-drug-startup-to-go",
        "published": "2026-08-24T15:30:04.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}